Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0WXQJL
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Vadastuximab talirine
|
|||||
| Synonyms |
Anti-CD33A targeted ADC; 33-A; SGN-CD33A; SGN CD33A; 33A
Click to Show/Hide
|
|||||
| Organization |
Seagen Inc.
|
|||||
| Drug Status |
Terminated in phase 3
|
|||||
| Indication |
In total 3 Indication(s)
Acute myelogenous leukemia [ICD11:2B33]
Terminated in phase 3
Myelodysplastic syndrome [ICD11:2A37]
Terminated in phase 2
Acute promyelocytic leukemia [ICD11:2A60]
Terminated in phase 1
|
|||||
| Drug-to-Antibody Ratio |
1.9
|
|||||
| Structure |
|
|||||
| Antibody Name |
Vadastuximab
|
Antibody Info | ||||
| Antigen Name |
Myeloid cell surface antigen CD33 (CD33)
|
Antigen Info | ||||
| Payload Name |
SGD-1882
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mc-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
SGD-1910
|
|||||
| Special Approval(s) |
Orphan drug(FDA)
|
|||||
| Puchem SID | ||||||
| Drugbank ID | ||||||
| DrugMap ID | ||||||
| TTD ID | ||||||
| ChEBI ID | ||||||
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Incomplete Count Recovery (CRi) |
26.00% (Placebo + HMA)
|
|||
| Patients Enrolled |
Older patients with newly diagnosed acute myeloid leukemia (AML).
|
||||
| Administration Dosage |
33A, iv, 10 mcg/kg, every 4 weeks plus azacitidine 75 mg/m2, SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m2, iv x 5 days, every 4 weeks; placebo plus plus azacitidine 75 mg/m2, SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m2, iv x 5 days, every 4 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02326584 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia. | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Complete Remission (CR) |
66.70% (Pre-allo Before Stem Cell Transplant)
|
|||
| Patients Enrolled |
Patients With Relapsed or Refractory AmL.
|
||||
| Administration Dosage |
Post-allo after stem cell transplant in Day 1 of each cycle; Pre-allo in Day 1 of each cycle plus melphalan 30 mg/m2/day iv and fludarabine 140 mg/m2 iv before stem cell transplant.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02785900 | Clinical Status | Phase 3 | ||
| Clinical Description | A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML). | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Efficacy Data | Complete Remission (CR) |
11.00% (all treated, dose escalation/expansion 40 ug/kg)
12.00% (efficacy evaluable, dose escalation/expansion 40 ug/kg) 22.00% (all treated treatment naive 40 ug/kg) 23.00% (efficacy evaluable, treatment naive 40 ug/kg) |
|||
| Patients Enrolled |
CD33-positive AmL (any level of CD33 expression as detected by local flow cytometric assessment) and had either newly diagnosed AmL (declining intensive induction/consolidation chemotherapy) or AmL relapsed after a minimum remission duration of 12 weeks after intensive induction/consolidation.
|
||||
| Administration Dosage |
Slow IV push on day 1 (5-60 ug/kg) or on days 1 and 4 (20 ug/kg) of 21-day cycles.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01902329 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia. | ||||
| Primary Endpoint |
The recommended monotherapy dose is 4.00 mg/kg.
|
||||
| Other Endpoint |
The complete remission rate (CRc) among the 69 patients in the dose-finding cohorts, was 19.00% (6.00% CR + 13.00% CRi, 95% confidence interval [CI], 10.40-30.10).
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Complete Remission (CR) |
30.00% (33A + HMA)
26.00% (Placebo + HMA) |
|||
| Patients Enrolled |
Older patients with newly diagnosed acute myeloid leukemia (AML).
|
||||
| Administration Dosage |
33A, iv, 10 mcg/kg, every 4 weeks plus azacitidine 75 mg/m2, SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m2, iv x 5 days, every 4 weeks; placebo plus plus azacitidine 75 mg/m2, SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m2, iv x 5 days, every 4 weeks.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02326584 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia. | ||||
| Experiment 5 Reporting the Activity Date of This ADC | [4] | ||||
| Efficacy Data | Complete Remission (CR) |
43.00% (all treated)
42.00% (secondary AmL) 34.00% (75 y old) 80.00% (FLT3/ITD+) 50.00% (MRC adv) 39.00% (Und. Myelo) |
|||
| Patients Enrolled |
New diagnosis of CD33-expressing AmL, they could not have received prior therapy with HMAs; however, prior low-intensity treatment, such as hydroxyurea for cytoreduction or other low-intensity therapies for preceding myelodysplastic syndrome (MDS), an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, with adequate baseline renal, hepatic, and pulmonary function.
Click to Show/Hide
|
||||
| Administration Dosage |
Azacitidine (75 mg/m2 subcutaneous/intravenous 7 days) or decitabine (20 mg/m2 intravenous 5 days) was administered per institutional standard. On the final day of HMA administration (day 7 of azacitidine treatment and day 5 of decitabine treatment), vadastuximab talirine (10 ug/kg) was administered via slow intravenous push (1-2 mL/min), after infusion of the HMA, as 28-day cycles for up to 4 cycles of treatment.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01902329 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia. | ||||
| Primary Endpoint |
The 30- and 60-day mortality rates were 2% and 8%, respectively. No DLTs or infusion-related reactions were observed in the combination cohort of this study.
|
||||
| Other Endpoint |
CR and CRi, was 70.00% (43% CR + 26% CRi, 95% CI, 55.70-81.70). Median RFS was 7.70 months (95% CI, 4.90-15.40) with 11.30 months (95% CI, 8.80-13.20) median OS.
|
||||
| Experiment 6 Reporting the Activity Date of This ADC | [5] | ||||
| Patients Enrolled |
Patients with operable HER2-positive primary breast cancer.
|
||||
| Administration Dosage |
Anthracycline then Trastuzumab Emtansine and Pertuzumab ; Anthracycline then Trastuzumab, Pertuzumab, and Taxane.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02614560 | Clinical Status | Phase 1/2 | ||
| Clinical Description | A phase 1/2 study of vadastuximab talirine administered in sequence with allogeneic hematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukemia (AML). | ||||
| Experiment 7 Reporting the Activity Date of This ADC | [6] | ||||
| Patients Enrolled |
Patients With acute myeloid leukemia (AML).
|
||||
| Administration Dosage |
SGN-CD33A iv in Day 1 or Days 1 and 4 of each cycle; High dose cytarabine + SGN-CD33A (28-day cycles); Standard dose cytarabine and daunorubicin + SGN-CD33A; standard dose cytarabine and daunorubicin + SGN-CD33A and High dose cytarabine + SGN-CD33A.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT01902329 | Clinical Status | Phase 1 | ||
| Clinical Description | A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia. | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% (Day 36) | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 100mcg/kg.
|
||||
| In Vitro Model | Erythroleukemia | HEL 92.1.7 cells (Multidrug resistance) | CVCL_2481 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 29.44% (Day 30) | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 30mcg/kg.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 47.77% (Day 36) | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 300mcg/kg.
|
||||
| In Vitro Model | Erythroleukemia | HEL 92.1.7 cells (Multidrug resistance) | CVCL_2481 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 78.95% (Day 38) | Negative CD33 expression (CD33-) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 100mcg/kg.
|
||||
| In Vitro Model | Anaplastic thyroid cancer | TF1-alpha cells (Multidrug resistance) | Homo sapiens | ||
| Experiment 5 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.41% (Day 36) | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 1000mcg/kg.
|
||||
| In Vitro Model | Erythroleukemia | HEL 92.1.7 cells (Multidrug resistance) | CVCL_2481 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.53% (Day 38) | Negative CD33 expression (CD33-) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 300mcg/kg.
|
||||
| In Vitro Model | Anaplastic thyroid cancer | TF1-alpha cells (Multidrug resistance) | Homo sapiens | ||
| Experiment 7 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.99% (Day 30) | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 100mcg/kg.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.99% (Day 40) | Negative CD33 expression (CD33-) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 300mcg/kg.
|
||||
| In Vitro Model | Anaplastic thyroid cancer | TF1-alpha cells (Multidrug resistance) | Homo sapiens | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.10 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=3,919) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG019 | Homo sapiens | ||
| Experiment 2 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.10 ng/mL | Moderate CD33 expression (CD33++; 6,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.20 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG022 | Homo sapiens | ||
| Experiment 4 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.20 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=1,355) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG014 | Homo sapiens | ||
| Experiment 5 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.20 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG023 | Homo sapiens | ||
| Experiment 6 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.20 ng/mL | High CD33 expression (CD33+++; CD33 MFI=10,762) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG018 | Homo sapiens | ||
| Experiment 7 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.20 ng/mL | High CD33 expression (CD33+++; CD33 MFI=11,850) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG015 | Homo sapiens | ||
| Experiment 8 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.40 ng/mL | Low CD33 expression (CD33+; CD33 MFI=107) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG003 | Homo sapiens | ||
| Experiment 9 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.90 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=5,817) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG002 | Homo sapiens | ||
| Experiment 10 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.00 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | HL-60 cells | CVCL_0002 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.00 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | KG-1 cells | CVCL_0374 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.00 ng/mL | Negative CD33 expression (CD33-; CD33 MFI=20) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG017 | Homo sapiens | ||
| Experiment 13 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 6.00 ng/mL | Negative CD33 expression (CD33-; CD33 MFI=49) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG001 | Homo sapiens | ||
| Experiment 14 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 6.00 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | SH-1 cells | CVCL_2191 | ||
| Experiment 15 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 7.00 ng/mL | High CD33 expression (CD33+++; CD33 MFI=23,223) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Erythroleukemia | HEL 92.1.7 cells | CVCL_2481 | ||
| Experiment 16 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 7.00 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | THP-1 cells | CVCL_0006 | ||
| Experiment 17 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 7.50 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | SIG-M5 cells | CVCL_1694 | ||
| Experiment 18 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 11.00 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=1,035) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG008 | Homo sapiens | ||
| Experiment 19 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 11.00 ng/mL | Low CD33 expression (CD33+; CD33 MFI=216) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG013 | Homo sapiens | ||
| Experiment 20 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 22.00 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Adult acute monocytic leukemia | U-937 cells | CVCL_0007 | ||
| Experiment 21 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 23.00 ng/mL | Low CD33 expression (CD33+; CD33 MFI=299) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG010 | Homo sapiens | ||
| Experiment 22 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 26.00 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | HNT-34 cells | CVCL_2071 | ||
| Experiment 23 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 32.00 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=1,184) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG004 | Homo sapiens | ||
| Experiment 24 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 33.00 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=6,598) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG011 | Homo sapiens | ||
| Experiment 25 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 49.00 ng/mL | Moderate CD33 expression (CD33++; CD33 MFI=2,278) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Anaplastic thyroid cancer | TF1-alpha cells (Multidrug resistance) | Homo sapiens | ||
| Experiment 26 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 61.00 ng/mL | Moderate CD33 expression (CD33++; 7,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Esophageal squamous cell carcinoma | TF-1 cells | CVCL_1759 | ||
| Experiment 27 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 68.00 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Adult acute myeloid leukemia | SH-2 cells | CVCL_2190 | ||
| Experiment 28 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 110.00 ng/mL | Negative CD33 expression (CD33-; CD33 MFI=0) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG009 | Homo sapiens | ||
| Experiment 29 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 110.00 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG020 | Homo sapiens | ||
| Experiment 30 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 110.00 ng/mL | Low CD33 expression (CD33+; CD33 MFI=353) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
|
||||
| In Vitro Model | Acute myeloid leukemia | Acute myeloid leukemia cells #SG012 | Homo sapiens | ||
| Experiment 31 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 1000.00 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Burkitt lymphoma | Ramos cells | CVCL_0597 | ||
| Experiment 32 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 1000.00 ng/mL | Low CD33 expression (CD33+; CD33 MFI=318) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Ovarian clear cell adenocarcinoma | ES-2 cells | CVCL_3509 | ||
| Experiment 33 Reporting the Activity Date of This ADC | [7] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 5000.00 ng/mL | High CD33 expression (CD33+++; 23,000 CD33 receptor copy number) | ||
| Method Description |
The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.